SECsense Logo

Neuphoria Therapeutics Inc. 8-K Report: Key Insights and Updates (Jan 2025)

$BNOX
Form 8-K
Filed on: 2025-01-14
Source
Neuphoria Therapeutics Inc. 8-K Report: Key Insights and Updates (Jan 2025)

Based on the provided section of the financial report, here are the key insights and extracted information:

  1. Entity Information:
  • Company Name: Neuphoria Therapeutics Inc.
  • CIK Number: 0001191070
  • State of Incorporation: Delaware (DE)
  • SEC File Number: 001-41157
  • EIN (Employer Identification Number): 99-3845449
  • Address: 100 Summit Dr, Burlington, MA 01803
  • Contact Number: +1 781 439 5551
  1. Filing Information:
  • Filing Type: 8-K (current report)
  • Filing Date: January 10, 2025
  1. Stock Information:
  • Type of Stock: Common Stock
  • Par Value: $0.00001 per share
  • Ticker Symbol: NEUP
  • Exchange: NASDAQ
  1. Reporting Period:
  • Report Date: January 10, 2025
  • This report covers information as of the same date.
  1. Measurement Units:
  • Currency: USD (United States Dollar)
  • Share Count: The report includes references to shares, although specific share counts or financial figures are not detailed in this excerpt.

Insights:

  • The document indicates a significant corporate event or update as Neuphoria Therapeutics Inc. filed an 8-K, which typically involves material events that shareholders should be aware of.
  • The filing is recent, dated January 10, 2025, suggesting that any information contained within could impact stock performance or investor sentiment shortly after.
  • The company's minimal par value for its common stock could indicate a strategy focused on maximizing share issuance flexibility.

This analysis can inform stakeholders about the company's current status, regulatory compliance, and potential market actions following the filing of the 8-K. Further examination of the complete filing would be necessary to uncover specific events or financial changes reported.